Compare Archer-Daniels-Midland Co (ADM) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Alnylam Pharmaceuticals, Inc. — how do they compare? Archer-Daniels-Midland Co trades at $80.14 (market cap $37.69B), while Alnylam Pharmaceuticals, Inc. trades at $324.32 (market cap $42.94B). The key difference: Archer-Daniels-Midland Co and Alnylam Pharmaceuticals, Inc. are close in size by market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ADM | ALNY | |
|---|---|---|
Market Cap | $37.69B | $42.94B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $491.22 |
52-Week Low | $53.54 | $278.09 |
Enterprise Value | $47.72B | $41.20B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
